

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock code: 1696)

**POLL RESULT OF THE EXTRAORDINARY GENERAL MEETING
HELD ON FEBRUARY 9, 2023**

Reference is made to the circular (the “Circular”) and the notice of the extraordinary general meeting (the “EGM”) of Sisram Medical Ltd 復銳醫療科技有限公司* (the “Company”) dated December 23, 2022. Unless otherwise defined in this announcement, terms used herein shall have the same meanings as ascribed to them in the Circular.

At the EGM held on February 9, 2023, the proposed resolution as set out in the notice of the EGM dated December 23, 2022 was taken by poll. The poll result is as follows:

Ordinary Resolution		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the sublicense agreement between Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (“Fosun Industrial”) and Sisram Medical (Tianjin) Limited* (復銳醫療科技(天津)有限公司) (“Sisram Tianjin”) dated October 26, 2022 with respect to the sublicense of rights by Fosun Industrial to Sisram Tianjin (including the transactions contemplated thereunder, but other than the Royalty Payments during the Rule 14A.53 Waiver Period which constitutes fully-exempt continuing connected transactions).	35,413,532 (100.000000%)	0 (0.000000%)	0 (-)

Notes:

- (a) Under the Israeli Companies Law, shareholders are required to declare to the Company whether they have a personal interest (including whether he/she/it is, or has an interest in connection with, a controlling shareholder) in the resolution relating to the sublicense agreement (including the transactions contemplated thereunder). Votes which are not accompanied by the personal interest declaration will be ignored and will not be counted.
- (b) As a majority of the votes were cast in favour of the resolution numbered 1, such resolution was duly passed as an ordinary resolution.

- (c) As at the date of the EGM, the total number of shares of the Company in issue was 467,292,609 shares, which is the total number of shares of the Company entitling the shareholders of the Company (the “**Shareholders**”) to attend and vote on the resolution at the EGM.
- (d) There were no shares entitling the Shareholders to attend and abstain from voting in favour of the resolution at the EGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (e) 331,911,200 shares held by Chindex Medical Limited and Ample Up Limited were required under the Listing Rules to abstain from voting on the resolution at the EGM.
- (f) None of the Shareholders has stated their intention in the Company’s Circular dated December 23, 2022 to vote against or to abstain from voting on the resolution at the EGM.
- (g) The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.
- (h) All directors of the Company attended the EGM.

By Order of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, February 9, 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as executive directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*